Trial Profile
Phase I trial of post transplant immunization with autologous myeloma idiotype-KLH [keyhole limpet hemocyanin]/GM-CSF [granulocyte macrophage colony-stimulating factors] in myeloma patients following autologous or allogeneic marrow or stem cell transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Melanoma vaccine (Primary) ; Sargramostim (Primary) ; Aldesleukin
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 02 May 2019 Status changed from active, no longer recruiting to completed.
- 26 Mar 2012 Planned end date added as 1 Dec 2002 as reported by ClinicalTrials.gov record.
- 26 Mar 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.